

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Weston, et al.
Serial No.: To Be Assigned
Filed: Concurrent Herewith
For: ANTISENSE HUMAN FUCOSYLTRANSFERASE SEQUENCES
AND METHODS OF USE THEREOF

Date: November 7, 2001

BOX PATENT APPLICATION
Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above application and calculation of claim fees, please amend the above-identified application as indicated below.

IN THE SPECIFICATION:

On page 1, line 9, please insert the following:

Cross-Reference to Related Applications

This application is a continuation of co-pending United States Application Serial No. 09/556,031, filed on April 20, 2000 (now allowed) which claims priority from U.S. Provisional Application Serial No. 60/131,068, filed April 26, 1999, the disclosures of which are incorporated by reference herein in their entirety.

IN THE CLAIMS:

Please cancel claims 1-8, 12-15 and 19-21.

Please amend Claim 9 as follows:

9. (Amended) A method of treating a subject afflicted with cancer, comprising administering to said subject an antisense oligonucleotide that hybridizes to a nucleic acid that encodes a fucosyltransferase, wherein said fucosyltransferase is selected from the group consisting of FUT3 and FUT6;

1005715-110701

In re: Weston, et al.
Serial No.: To Be Assigned
Filed: Concurrently Herewith
Page 2 of 8

said oligonucleotide selected from the group consisting of oligonucleotides consisting of the sequence:

AGGCCATGGCAGGTTTCCTG (SEQ ID NO: 1);
AACTGAAGATCTACAAAAGA (SEQ ID NO: 2);
ACCAAGGTTCTGGAAAGAGA (SEQ ID NO: 3);
TGTAGGTCACCTGAGTGTGA (SEQ ID NO: 4);
GCTGCACCCAGGGGATCCAT (SEQ ID NO: 5);
TCTCGTAGTTGCTTCTGCTG (SEQ ID NO: 6);
GAGCGAGGCCGCAGCGTCTC (SEQ ID NO: 7);
ATCAGCCAGAACCATCACTC (SEQ ID NO: 8);
ACCTGTACCCTATAAGTGGT (SEQ ID NO: 9);
GATAACTTACCTGGAGAGGC (SEQ ID NO: 10);
TTAGGGTTGGACATGATATC (SEQ ID NO: 11);
CCCACTCCTGCAGGGCAGTG (SEQ ID NO: 12);
GGGTCTTCACCACTGGAGAG (SEQ ID NO: 13);
AGTGAAAAGGCTGACCTGAA (SEQ ID NO: 14);
TGGATGCCCCGTGACACTGGG (SEQ ID NO: 15);
GCCGGGCCCAGGGGATCCAT (SEQ ID NO: 16);
CACCCAGATCCAGCGTCCCA (SEQ ID NO: 17);
ATCTCCTGACCTTGTGATCC (SEQ ID NO: 18);
GATCTCCTGACCTAGGAAGA (SEQ ID NO: 19);
TTCTCACTCAGTTGGCCCAT (SEQ ID NO: 20);
CCAACCACCACACCTGTCAT (SEQ ID NO: 21);
GGACGAGTAACAGCTGGATT (SEQ ID NO: 22);
GCTTGCTGCACCCAGGGGATC (SEQ ID NO: 23);
CTCTGCCGCTCCTGGACACTGCTGC (SEQ ID NO: 24);

and continuous 15 or 18 nucleotide fragments of the sequences listed above in an amount effective to treat said cancer.

10005715-110701

Please amend Claim 16 as follows:

16. (Amended) A method of treating a subject afflicted with cancer, comprising administering to said subject a vector that comprises and expresses an exogenous nucleic acid encoding an antisense oligonucleotide that hybridizes to an endogenous nucleic acid that encodes a fucosyltransferase, wherein said fucosyltransferase is selected from the group consisting of FUT3 and FUT6 and wherein said nucleic acid is selected from the group consisting of:

AGGCCATGGCAGGTTTCCTG (SEQ ID NO: 1);
AACTGAAGATCTACAAAAGA (SEQ ID NO: 2);
ACCAAGGTTCTGGAAAGAGA (SEQ ID NO: 3);
TGTAGGTCACCTGAGTGTGA (SEQ ID NO: 4);
GCTGCACCCAGGGGATCCAT (SEQ ID NO: 5);
TCTCGTAGTTGCTTCTGCTG (SEQ ID NO: 6);
GAGCGAGGCCGCAGCGTCTC (SEQ ID NO: 7);
ATCAGCCAGAACCATCACTC (SEQ ID NO: 8);
ACCTGTACCCTATAAGTGGT (SEQ ID NO: 9);
GATAACTTACCTGGAGAGGC (SEQ ID NO: 10);
TTAGGGTTGGACATGATATC (SEQ ID NO: 11);
CCCACTCCTGCAGGGCAGTG (SEQ ID NO: 12);
GGGTCTTCACTGAGAG (SEQ ID NO: 13);
AGTGAAAAGGCTGACCTGAA (SEQ ID NO: 14);
TGGATGCCCGTGACACTGGG (SEQ ID NO: 15);
GCCGGGCCAGGGGATCCAT (SEQ ID NO: 16);
CACCCAGATCCAGCGTCCCA (SEQ ID NO: 17);
ATCTCCTGACCTTGTGATCC (SEQ ID NO: 18);
GATCTCCTGACCTAGGAAGA (SEQ ID NO: 19);
TTCTCACTCAGTTGGCCCAT (SEQ ID NO: 20);
CCAACCACCACACCTGTCAT (SEQ ID NO: 21);
GGACGAGTAACAGCTGGATT (SEQ ID NO: 22);
GCTTGGCTGCACCCAGGGGATC (SEQ ID NO: 23);
CTCTGCCGCTCCTGGACACTGCTGC (SEQ ID NO: 24);

1005715-140794

1 **2** **3** **4**

1900-1901 1902-1903 1904-1905 1906-1907

1908-1909 1910-1911 1912-1913 1914-1915

1916-1917 1918-1919 1920-1921 1922-1923

1924-1925 1926-1927 1928-1929 1930-1931

1932-1933 1934-1935 1936-1937 1938-1939

1940-1941 1942-1943 1944-1945 1946-1947

1948-1949 1950-1951 1952-1953 1954-1955

1956-1957 1958-1959 1960-1961 1962-1963

1964-1965 1966-1967 1968-1969 1970-1971

1972-1973 1974-1975 1976-1977 1978-1979

1980-1981 1982-1983 1984-1985 1986-1987

1988-1989 1990-1991 1992-1993 1994-1995

1996-1997 1998-1999 2000-2001 2002-2003

2004-2005 2006-2007 2008-2009 2010-2011

2012-2013 2014-2015 2016-2017 2018-2019

2020-2021 2022-2023 2024-2025 2026-2027

2028-2029 2030-2031 2032-2033 2034-2035

2036-2037 2038-2039 2040-2041 2042-2043

2044-2045 2046-2047 2048-2049 2050-2051

2052-2053 2054-2055 2056-2057 2058-2059

2060-2061 2062-2063 2064-2065 2066-2067

2068-2069 2070-2071 2072-2073 2074-2075

2076-2077 2078-2079 2080-2081 2082-2083

2084-2085 2086-2087 2088-2089 2090-2091

2092-2093 2094-2095 2096-2097 2098-2099

2100-2101 2102-2103 2104-2105 2106-2107

2108-2109 2110-2111 2112-2113 2114-2115

2116-2117 2118-2119 2120-2121 2122-2123

2124-2125 2126-2127 2128-2129 2130-2131

2132-2133 2134-2135 2136-2137 2138-2139

2140-2141 2142-2143 2144-2145 2146-2147

2148-2149 2150-2151 2152-2153 2154-2155

2156-2157 2158-2159 2160-2161 2162-2163

2164-2165 2166-2167 2168-2169 2170-2171

2172-2173 2174-2175 2176-2177 2178-2179

2180-2181 2182-2183 2184-2185 2186-2187

2188-2189 2190-2191 2192-2193 2194-2195

2196-2197 2198-2199 2200-2201 2202-2203

2204-2205 2206-2207 2208-2209 2210-2211

2212-2213 2214-2215 2216-2217 2218-2219

2220-2221 2222-2223 2224-2225 2226-2227

2228-2229 2230-2231 2232-2233 2234-2235

2236-2237 2238-2239 2240-2241 2242-2243

2244-2245 2246-2247 2248-2249 2250-2251

2252-2253 2254-2255 2256-2257 2258-2259

2260-2261 2262-2263 2264-2265 2266-2267

2268-2269 2270-2271 2272-2273 2274-2275

2276-2277 2278-2279 2280-2281 2282-2283

2284-2285 2286-2287 2288-2289 2290-2291

2292-2293 2294-2295 2296-2297 2298-2299

2300-2301 2302-2303 2304-2305 2306-2307

2308-2309 2310-2311 2312-2313 2314-2315

2316-2317 2318-2319 2320-2321 2322-2323

2324-2325 2326-2327 2328-2329 2330-2331

2332-2333 2334-2335 2336-2337 2338-2339

2340-2341 2342-2343 2344-2345 2346-2347

2348-2349 2350-2351 2352-2353 2354-2355

2356-2357 2358-2359 2360-2361 2362-2363

2364-2365 2366-2367 2368-2369 2370-2371

2372-2373 2374-2375 2376-2377 2378-2379

2380-2381 2382-2383 2384-2385 2386-2387

2388-2389 2390-2391 2392-2393 2394-2395

2396-2397 2398-2399 2400-2401 2402-2403

2404-2405 2406-2407 2408-2409 2410-2411

2412-2413 2414-2415 2416-2417 2418-2419

2420-2421 2422-2423 2424-2425 2426-2427

2428-2429 2430-2431 2432-2433 2434-2435

2436-2437 2438-2439 2440-2441 2442-2443

2444-2445 2446-2447 2448-2449 2450-2451

2452-2453 2454-2455 2456-2457 2458-2459

2460-2461 2462-2463 2464-2465 2466-2467

2468-2469 2470-2471 2472-2473 2474-2475

2476-2477 2478-2479 2480-2481 2482-2483

2484-2485 2486-2487 2488-2489 2490-2491

2492-2493 2494-2495 2496-2497 2498-2499

2500-2501 2502-2503 2504-2505 2506-2507

2508-2509 2510-2511 2512-2513 2514-2515

2516-2517 2518-2519 2520-2521 2522-2523

2524-2525 2526-2527 2528-2529 2530-2531

2532-2533 2534-2535 2536-2537 2538-2539

2540-2541 2542-2543 2544-2545 2546-2547

2548-25

Please add Claim 22:

22. (New) A method according to claim 9, wherein said oligonucleotide does not activate RNase H.


In re: Weston, et al.
Serial No.: To Be Assigned
Filed: Concurrently Herewith
Page 5 of 8

REMARKS

Attached hereto is a marked-up version of the changes made to the specification and claims by the current Preliminary Amendment. The attached page is captioned "Version with markings to show changes made."

Applicants respectfully request that a timely Notice of Allowance be issued in this case.

Respectfully submitted,



Jarett K. Abramson
Attorney for Applicants
Registration No. 47,376




20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label number EL 920739550US
Date of Deposit: November 7, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to BOX PATENT APPLICATION, Commissioner for Patents, Washington, DC 20231.



Candi L. Riggs

Date of Signature: November 7, 2001

10005715-110701

In re: Weston, et al.
Serial No.: To Be Assigned
Filed: Concurrently Herewith
Page 6 of 8

Version With Markings To Show Changes Made

A marked up version of each of the presently amended claims and specification, highlighting the changes thereto, follows:

IN THE SPECIFICATION:

New paragraph at page 1, line 2, has been added as follows:

Cross-Reference to Related Applications

This application is a continuation of co-pending United States Application Serial No. 09/556,031, filed on April 20, 2000 (now allowed) which claims priority from U.S. Provisional Application Serial No. 60/131,068, filed April 26, 1999, the disclosures of which [is] are incorporated by reference herein in [its] their entirety.

IN THE CLAIMS:

Claims 1-8, 12-15 and 19-21 have been cancelled.

Claim 9 has been amended as follows:

9. (Amended) A method of treating a subject afflicted with cancer, comprising administering to said subject an antisense oligonucleotide [according to claim 1] that hybridizes to a nucleic acid that encodes a fucosyltransferase, wherein said fucosyltransferase is selected from the group consisting of FUT3 and FUT6;

said oligonucleotide selected from the group consisting of oligonucleotides consisting of the sequence:

AGGCCATGGCAGGTTTCCTG (SEQ ID NO: 1);

AACTGAAGATCTACAAAAGA (SEQ ID NO: 2);

ACCAAGGTTCTGGAAAGAGA (SEQ ID NO: 3);

TGTAGGTCACCTGAGTGTGA (SEQ ID NO: 4);

GCTGCACCCAGGGGATCCAT (SEQ ID NO: 5);

TCTCGTAGTTGCTTCTGCTG (SEQ ID NO: 6);

GAGCGAGGCCGCAGCGTCTC (SEQ ID NO: 7);

ATCAGCCAGAACCATCACTC (SEQ ID NO: 8);

ACCTGTACCCTATAAGTGGT (SEQ ID NO: 9);

In re: Weston, et al.
Serial No.: To Be Assigned
Filed: Concurrently Herewith
Page 7 of 8

GATAACTTACCTGGAGAGGC (SEQ ID NO: 10);
TTAGGGTTGGACATGATATC (SEQ ID NO: 11);
CCCACTCCTGCAGGGCAGTG (SEQ ID NO: 12);
GGGTCTTCACCACTGGAGAG (SEQ ID NO: 13);
AGTGAAAAGGCTGACCTGAA (SEQ ID NO: 14);
TGGATGCCCCGTGACACTGGG (SEQ ID NO: 15);
GCCGGGCCCAGGGGATCCAT (SEQ ID NO: 16);
CACCCAGATCCAGCGTCCCA (SEQ ID NO: 17);
ATCTCCTGACCTTGTGATCC (SEQ ID NO: 18);
GATCTCCTGACCTAGGAAGA (SEQ ID NO: 19);
TTCTCACTCAGTTGGCCCAT (SEQ ID NO: 20);
CCAACCACCACACCTGTCAT (SEQ ID NO: 21);
GGACGAGTAACAGCTGGATT (SEQ ID NO: 22);
GCTTGGCTGCACCCAGGGGATC (SEQ ID NO: 23);
CTCTGCCGCTCCTGGACACTGCTGC (SEQ ID NO: 24);

and continuous 15 or 18 nucleotide fragments of the sequences listed above in an amount effective to treat said cancer.

Claim 16 has been amended as follows:

16. (Amended) A method of treating a subject afflicted with cancer, comprising administering to said subject a vector [according to claim 14] that comprises and expresses an exogenous nucleic acid encoding an antisense oligonucleotide that hybridizes to an endogenous nucleic acid that encodes a fucosyltransferase, wherein said fucosyltransferase is selected from the group consisting of FUT3 and FUT6 and wherein said nucleic acid is selected from the group consisting of:

AGGCCATGGCAGGTTTCCTG (SEQ ID NO: 1);
AACTGAAGATCTACAAAAGA (SEQ ID NO: 2);
ACCAAGGTCTTGAAAGAGA (SEQ ID NO: 3);
TGTAGGTCACCTGAGTGTGA (SEQ ID NO: 4);
GCTGCACCCAGGGGATCCAT (SEQ ID NO: 5);
TCTCGTAGTTGCTTCTGCTG (SEQ ID NO: 6);

In re: Weston, et al.
Serial No.: To Be Assigned
Filed: Concurrently Herewith
Page 8 of 8

GAGCGAGGCCGCAGCGTCTC (SEQ ID NO: 7);
ATCAGCCAGAACCATCACTC (SEQ ID NO: 8);
ACCTGTACCCTATAAGTGGT (SEQ ID NO: 9);
GATAACTTACCTGGAGAGGC (SEQ ID NO: 10);
TTAGGGTTGGACATGATATC (SEQ ID NO: 11);
CCCACTCCTGCAGGGCAGTG (SEQ ID NO: 12);
GGGTCTTCACCACTGGAGAG (SEQ ID NO: 13);
AGTGAAAAGGCTGACCTGAA (SEQ ID NO: 14);
TGGATGCCCCGTGACACTGGG (SEQ ID NO: 15);
GCCGGGGCCCAGGGGATCCAT (SEQ ID NO: 16);
CACCCAGATCCAGCGTCCCA (SEQ ID NO: 17);
ATCTCCTGACCTTGTGATCC (SEQ ID NO: 18);
GATCTCCTGACCTAGGAAGA (SEQ ID NO: 19);
TTCTCACTCAGTTGGCCCAT (SEQ ID NO: 20);
CCAACCACACACCTGTCAT (SEQ ID NO: 21);
GGACGAGTAACAGCTGGATT (SEQ ID NO: 22);
GCTTGGCTGCACCCAGGGGATC (SEQ ID NO: 23);
CTCTGCCGCTCCTGGACACTGCTGC (SEQ ID NO: 24);

and continuous 15 or 18 nucleotide fragments of the sequences listed above in an amount effective to treat said cancer.

Claim 22 has been added as follows:

22. (New) A method according to claim 9, wherein said oligonucleotide does not activate RNase H.

*** END ***